Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

An Inflammatory Deal: Bristol Commits Up To $2.3bn To Buy IFM Therapeutics

LungCancerCells_1200x675

Related Content

Scrip's Rough Guide To IDO

May 18 2017

Immuno-Oncology Attracts Big Deal Dollars For Biotechs

Jun 27 2016

VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs

Jun 25 2016

iTeos: Developing IO Therapeutics For Hot And Cold Tumors

Mar 15 2017

Aduro gets $200m as Novartis steps up immuno-oncology

Mar 30 2015

Flexus flips IDO inhibitors to Bristol-Myers for up to $1.25bn

Feb 24 2015

Related Companies

Bristol Myers Squibb Company

IFM Therapeutics

Lycera Corporation

Novartis AG

Aduro Biotech, Inc.

iTeos Therapeutics Inc.

Bristol Myers Squibb Company

Additional Topics

M & A Deals ImmunoOncology Commercial Cancer BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window